Moderna’s flu shot crosses FDA finish line, bouncing back from regulatory roadblock
NDA FilingmFLUVISAPositive
AI Analysis
Summary
Moderna's flu vaccine mFLUVISA overcome a February FDA refusal-to-file letter after the agency accepted a revised submission, with an advisory committee unanimously supporting its approval in June.
Outcome Details
FDA initially issued refusal-to-file letter in February but backtracked and accepted revised submission. Advisory committee unanimously backed approval in June.
Importance:8/10
Sentiment:
0.70
FDA approvalvaccineregulatory approvalAdCom positive
Related Companies
Read the original article
Published by BioSpace on August 6, 2026 11:46 AM